Moreover, these findings adds credence to the hypothesis that therapies aimed at decreasing the activity of PAD2-induced citrullination in the hippocampus might reverse the disease progression and afford better clinical outcomes in the AD patients [70]. The gene discussed is PADI2; the disease is Alzheimer disease.